Search results for "Manchester"

showing 10 items of 20 documents

Genome-wide association meta-analysis highlights light-induced signaling as a driver for refractive error

2018

Skin affections after sulfur mustard (SM) exposure include erythema, blister formation and severe inflammation. An antidote or specific therapy does not exist. Anti-inflammatory compounds as well as substances counteracting SM-induced cell death are under investigation. In this study, we investigated the benzylisoquinoline alkaloide berberine (BER), a metabolite in plants like berberis vulgaris, which is used as herbal pharmaceutical in Asian countries, against SM toxicity using a well-established in vitro approach. Keratinocyte (HaCaT) mono-cultures (MoC) or HaCaT/THP-1 co-cultures (CoC) were challenged with 100, 200 or 300 mM SM for 1 h. Post-exposure, both MoC and CoC were treated with 1…

0301 basic medicineAdultMaleCell typeResearchInstitutes_Networks_Beacons/MICRAIn silicotaittovirheetGenome-wide association studyRetinal Pigment EpitheliumBiologyBlindnessPolymorphism Single NucleotideSensory disorders Donders Center for Medical Neuroscience [Radboudumc 12]ArticleRetinaWhite People03 medical and health sciencesHIGH-GRADE MYOPIA ; RETINAL-PIGMENT EPITHELIUM ; SEROTONIN PATHWAY GENES ; FORM-DEPRIVATION MYOPIA ; COMMON VARIANTS ; OCULAR GROWTH ; RETINITIS-PIGMENTOSA ; GENOTYPE IMPUTATION ; MISSENSE MUTATIONS ; DOPAMINE-RECEPTORSAsian Peoplerefractive errorsRetinitis pigmentosaGeneticsmedicineMyopiaJournal ArticleHumansGenetic Predisposition to Disease610 Medicine & healthRegulation of gene expressionRetinaRetinal pigment epitheliummedicine.diseaseRefractive Errors030104 developmental biologymedicine.anatomical_structureManchester Institute for Collaborative Research on AgeingGene Expression Regulationgenetic factorsEye disorderFemalesense organsgeneettiset tekijätNeuroscienceGenome-Wide Association StudySignal Transduction
researchProduct

Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants:a Prospective Lynch Syndrome Database r…

2021

Purpose: This study aimed to report the uptake of hysterectomy and/or bilateral salpingo-oophorectomy (BSO) to prevent gynaecological cancers (risk-reducing surgery [RRS]) in carriers of pathogenic MMR (path_MMR) variants.Methods: The Prospective Lynch Syndrome Database (PLSD) was used to investigate RRS by a cross-sectional study in 2292 female path_MMR carriers aged 30-69 years.Results: Overall, 144, 79, and 517 carriers underwent risk-reducing hysterectomy, BSO, or both combined, respectively. Two-thirds of procedures before 50 years of age were combined hysterectomy and BSO, and 81% of all procedures included BSO. Risk-reducing hysterectomy was performed before age 50 years in 28%, 25%,…

0301 basic medicineCancer ResearchOophorectomyDatabases FactualColorectal cancerSURGERYmedicine.medical_treatmentCàncer d'ovaricomputer.software_genreDNA Mismatch Repair0302 clinical medicineEndometrial cancermunasarjasyöpäMedicineProspective StudiesColectomySalpingo-oophorectomy/methodsDatabaseManchester Cancer Research CentreCOLON-CANCERMLH1WOMENMiddle AgedPrognosisLynch syndrome3. Good healthkohdunrungon syöpäOncologyCOLECTOMY030220 oncology & carcinogenesisFemaleBiomarkers Tumor/geneticsAdultHeterozygoteGenital Neoplasms FemaleSalpingo-oophorectomyHysterectomy03 medical and health sciencesGenital Neoplasms Female/prevention & controlOvarian cancerColorectal Neoplasms Hereditary Nonpolyposis/geneticsBiomarkers TumorMortalitatHumansHysterectomy/methodsMortalityLynchin oireyhtymäRisk-reducing surgeryAgedHysterectomybusiness.industryEndometrial cancerResearchInstitutes_Networks_Beacons/mcrcCancerOophorectomyMSH63126 Surgery anesthesiology intensive care radiologymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisMSH2030104 developmental biologyCross-Sectional StudiesLynch syndromePMS2Càncer d'endometriMutationkohdunpoistobusinessOvarian cancercomputerFollow-Up Studies
researchProduct

E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell death

2018

International audience; E2F1 is the main pro-apoptotic effector of the pRB-regulated tumor suppressor pathway by promoting the transcription of various pro-apoptotic proteins. We report here that E2F1 partly localizes to mitochondria, where it favors mitochondrial outer membrane permeabilization. E2F1 interacts with BCL-xL independently from its BH3 binding interface and induces a stabilization of BCL-xL at mitochondrial membranes. This prevents efficient control of BCL-xL over its binding partners, in particular over BAK resulting in the induction of cell death. We thus identify a new, non-BH3-binding regulator of BCL-xL localization dynamics that influences its anti-apoptotic activity.

0301 basic medicineProgrammed cell deathTranscription Geneticbcl-X ProteinRegulatorBcl-xL[SDV.CAN]Life Sciences [q-bio]/CancerBCL-xL mobilityMitochondrionBiochemistrylaw.invention[ SDV.CAN ] Life Sciences [q-bio]/CancerE2F1 Subject Category Autophagy & Cell Death03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerlawBCL-2 familyCell Line TumorGeneticsJournal ArticleHumansE2F1Molecular BiologyCell DeathbiologyManchester Cancer Research CentreEffectorChemistryResearchInstitutes_Networks_Beacons/mcrcScientific ReportsapoptosisSubcellular localizationMitochondriaCell biologyProtein Transportbcl-2 Homologous Antagonist-Killer Protein030104 developmental biologyGene Expression RegulationProto-Oncogene Proteins c-bcl-2biology.proteinSuppressorbiological phenomena cell phenomena and immunityExtracellular SpaceE2F1 Transcription FactorProtein Binding
researchProduct

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma : results From the Open-Label, Multicenter, Phase II DAWN Study

2018

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee–assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classFollicular lymphomaPhases of clinical researchTyrosine-kinase inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesRecurrenceT-Lymphocyte SubsetsChemoimmunotherapyInternal medicineBiomarkers TumormedicineHumansLymphoma FollicularProtein Kinase InhibitorsAgedAged 80 and overManchester Cancer Research Centrebusiness.industryResearchInstitutes_Networks_Beacons/mcrcAdenineMiddle Agedmedicine.diseaseLymphomaPyrimidinesTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisIbrutinibPyrazolesFemaleRefractory Follicular LymphomabusinessProgressive disease030215 immunology
researchProduct

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale…

2021

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid research methodologies and quality trial implementation. Studies incorporating flawed design, implementation, or data analysis may generate outcomes that exaggerate true benefit and are not generalisable. Failure to either indicate or penalise studies with bias undermines the intention and diminishes the integrity of ESMO-MCBS scores. This review aimed to evaluate the adequacy of the ESMO-MCBS to address bias generated by flawed design, im…

Data Analysis:técnicas de investigación::métodos::diseño de la investigación [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Cancer Researchbiasmedia_common.quotation_subjectclinical trial reportingESMO-MCBS:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]ReviewMedical Oncologyclinical trial implementation:Other subheadings::Other subheadings::/drug therapy [Other subheadings]:neoplasias [ENFERMEDADES]:profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES]Neoplasmsclinical trial analysis:Investigative Techniques::Methods::Research Design [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Agency (sociology)HumansQuality (business):Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]health care economics and organizationsmedia_commonActuarial scienceManchester Cancer Research CentreCàncer - TractamentResearchInstitutes_Networks_Beacons/mcrcClinical study designHealth technologyGénéralitésPublication biasclinical trial designAssaigs clínics - Disseny:Neoplasms [DISEASES]Clinical trialCritical appraisalOncologyResearch DesignScale (social sciences)PsychologyESMO Open
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Hadron therapy information sharing prototype

2013

The European PARTNER project developed a prototypical system for sharing hadron therapy data. This system allows doctors and patients to record and report treatment-related events during and after hadron therapy. It presents doctors and statisticians with an integrated view of adverse events across institutions, using open-source components for data federation, semantics, and analysis. There is a particular emphasis upon semantic consistency, achieved through intelligent, annotated form designs. The system as presented is ready for use in a clinical setting, and amenable to further customization. The essential contribution of the work reported here lies in the novel data integration and rep…

Health Physics and Radiation EffectsDatabases FactualComputer scienceHealth Toxicology and MutagenesisInformation Disseminationdata federationcancer informaticsweb portalSemanticscomputer.software_genreHealth informaticsPersonalizationAccess to Information03 medical and health sciences0302 clinical medicineSoftwareeHealthProton Therapyproton therapyRadiobiology and ClinicsHumansRadiology Nuclear Medicine and imaging030304 developmental biology0303 health sciencesRadiationManchester Cancer Research Centrebusiness.industryInformation DisseminationInformation sharingResearchInstitutes_Networks_Beacons/mcrcData scienceEurope030220 oncology & carcinogenesisInterdisciplinary CommunicationeHealthhadron therapybusinesscomputerAlgorithmsMedical InformaticsSoftwareData integration
researchProduct

Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

2020

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a …

MaleCancer ResearchOutcome AssessmentInternational CooperationSettore MED/18 - CHIRURGIA GENERALESettore MED/19 - Chirurgia Plastica030230 surgeryAged; Aged 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Postoperative Complications; SARS-CoV-2Cohort Studies0302 clinical medicineOperating theaterPostoperative Complicationscohort studiesNeoplasmsHealth caremiddle agedOutcome Assessment Health Care80 and overMedicineLungCancerCOVID-19/epidemiologyAged 80 and overOUTCOMESManchester Cancer Research CentrePulmonary ComplicationORIGINAL REPORTSMiddle AgedagedOncologyElective Surgical Procedures030220 oncology & carcinogenesisPneumonia & InfluenzaFemalePatient SafetyElective Surgical ProcedureLife Sciences & Biomedicine6.4 SurgeryCohort studyHumanmedicine.medical_specialtyelective surgical procedures/methodsLogistic ModelCritical CareAged; Aged; 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment; Health Care; Postoperative Complications; SARS-CoV-2Clinical SciencesOncology and CarcinogenesisEpidemic[SDV.CAN]Life Sciences [q-bio]/Cancer-.cancer surgery ; COVID-19 ; SARS-CoV-2 pandemicepidemicsCOVIDSurg CollaborativeNOoutcome assessment health care/methods03 medical and health sciencesmaleSettore MED/28 - Malattie OdontostomatologicheClinical ResearchHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryEpidemicsElective Cancer Surgery in SARS-CoV-2 Elective Cancer Surgery in COVID-19 covid 19 sars-cov-2AgedScience & TechnologyElective Surgical Procedurebusiness.industrySARS-CoV-2PreventionResearchInstitutes_Networks_Beacons/mcrcEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical SciencesPneumoniaOdds ratiomedicine.diseaseHealth CarePneumoniaGood Health and Well Beingneoplasms/surgeryLogistic Modelscritical care/methodsEmergency medicinepostoperative complications/prevention & controlNeoplasmPostoperative ComplicationCohort Studiebusinessaged 80 and overSARS-CoV-2/physiologylogistic models
researchProduct

Repositioning of the global epicentre of non-optimal cholesterol

2020

Publisher's version (útgefin grein)

MaleMyocardial Ischemia/bloodBLOOD-PRESSUREtriglicéridos0302 clinical medicineCardiovascular diseases ; Risk factorsHDL cholesterol80 and overCARDIOVASCULAR RISK-FACTORSPublic health surveillance//purl.org/pe-repo/ocde/ford#3.02.04 [https]BlóðrásarsjúkdómarSocioeconomicsmediana edadComputingMilieux_MISCELLANEOUSPOPULATIONHypercholesterolemia/bloodAged 80 and overCholesterol HDL/bloodancianoeducation.field_of_studyKólesterólriskitekijätadulto3. Good healthadulto jovenTriglycerides/bloodCardiovascular diseasesGeographyCholesterolManchester Institute for Collaborative Research on AgeingCholesterol LDL/bloodDENSITY-LIPOPROTEIN CHOLESTEROLEndokrinologi och diabetesNCD Risk Factor Collaboration (NCD-RisC)Science & Technology - Other Topics//purl.org/becyt/ford/3 [https]Westernteorema de Bayesmedicine.medical_specialtyResearchInstitutes_Networks_Beacons/MICRAHDLMedicinaHypercholesterolemiahipercolesterolemiaNursingHEART-DISEASEEndocrinology and DiabetesHigh blood cholesterol.HDL-kolesteroliArticleLDLravintoHealth risk assessment03 medical and health sciences//purl.org/becyt/ford/3.3 [https]SDG 3 - Good Health and Well-beingBlood cholesterolHumanseducationSERUM-CHOLESTEROLVLAGAgedScience & TechnologyCholesterolPublic healthOmvårdnadHuman healthVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710Bayes TheoremATHEROSCLEROSIS SOCIETYRisk factorschemistryLipid-lowering medicationsFaculdade de Ciências SociaisEast and southeast Asiaalueelliset erotInternationalityNutrition and Disease[SDV]Life Sciences [q-bio]kolesterolihumanosMyocardial IschemiaMedizinadolescenteNon-HDL cholesterolBlood lipids030204 cardiovascular system & hematologyisquemia miocárdicachemistry.chemical_compoundCholesterol epidemiologyMEDICATION USEVoeding en ZiekteMedicine and Health SciencesAdolescent; Adult; Aged; Aged 80 and over; Bayes Theorem; Cholesterol HDL; Cholesterol LDL; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Stroke; Triglycerides; Young Adult; Internationality030212 general & internal medicine2. Zero hungerMultidisciplinaryMortality rateRepositioningStroke/blood1. No povertyPublic Health Global Health Social Medicine and EpidemiologycolesterolMiddle AgedVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 7103142 Public health care science environmental and occupational healthPeer reviewStrokeMultidisciplinary SciencesTrend analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalelipids (amino acids peptides and proteins)LIPIDSAdultAdolescentGeneral Science & TechnologyPopulationepicentre20-YEAR TRENDSYoung AdultmedicineLife Scienceddc:610accidente cerebrovascularDisease burdenTriglyceridesNutritionHigh density lipoproteinsnon-optimal cholesterolCholesterol HDLinternacionalidadCholesterol LDLTreatmentFolkhälsovetenskap global hälsa socialmedicin och epidemiologi
researchProduct

Pan-cancer analysis of whole genomes

2020

Publisher's version (útgefin grein)

Maletert promoter mutationsCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]DNA Mutational AnalysisNormal tissuesystematic analysisGermlineTranscriptome0302 clinical medicineAetiologyCàncerCellular SenescenceCancer0303 health sciencesdna-damageMassive parallel sequencingPan cancerREARRANGEMENTSHigh-Throughput Nucleotide SequencingGenomicsSciences bio-médicales et agricolesTelomereCOMPREHENSIVE3. Good healthTERT PROMOTER MUTATIONSsignatures030220 oncology & carcinogenesisScience & Technology - Other TopicsErfðarannsóknirHuman:Informàtica::Aplicacions de la informàtica::Bioinformàtica [Àrees temàtiques de la UPC]EvolutionRNA SplicingGenomicsArticleEvolution MolecularStructural variationRC025403 medical and health sciencesSDG 3 - Good Health and Well-beingGeneticgenomicsSYSTEMATIC ANALYSISGeneticsGenomics--Databases.HumansGenetic TestingMolecular BiologySIGNATURESWhole genome sequencing1000 MultidisciplinaryChromothripsisScience & TechnologyRC0254 Neoplasms. Tumors. Oncology (including Cancer)Information DisseminationResearchInstitutes_Networks_Beacons/mcrcPreventionBiology and Life SciencesMolecularOncogenesCloud Computingmedicine.diseaseGenòmicaCompute cloudsMutation570 Life sciences; biologyCOMPREHENSIVE CHARACTERIZATIONGenèticaWhole Genome Sequencing--methodsBackground informationDNA Mutational Analysis ; Evolution ; Genetic / genetics ; Genome ; Genomics ; Germ-Line Mutation / genetics ; High-Throughput Nucleotide Sequencing ; Human / genetics ; Humans ; ICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumMedizinGenomeWhole-genomeGenome mappingNeoplasms2.1 Biological and endogenous factorsPromoter Regions GeneticCàncer -- Aspectes genèticsTelomeraseGeneticsWomen's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]MultidisciplinaryChromothripsisGenomeManchester Cancer Research Centregenomics cancer profiling3rd-DAS10124 Institute of Molecular Life SciencesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]Multidisciplinary SciencesParallel sequencingICGC/TCGA Pan-Cancer Analysis of Whole Genomes ConsortiumFemaleprofilingMedical GeneticsEngineering sciences. TechnologyBiotechnologyGeneral Science & TechnologyThe Cancer Genome Atlas610 Medicine & healthComputational biologyQH426 GeneticsBiologyConsortium of the International Cancer Genome ConsortiumPromoter RegionsGermline mutationPan-cancer analysisKrabbameinsrannsóknirmedicinecancerddc:610QH426Germ-Line MutationMedicinsk genetikKrabbamein030304 developmental biologyCell ProliferationLANDSCAPEGenome Humancomprehensive characterizationPan-cancer analysis of whole genomesPoint mutationHuman GenomeCancerReproducibility of ResultsSOMATIC MUTATIONSEVOLUTIONCancer sequencing Chromothripsis telomereDNA-DAMAGEMutagenesisPATTERNS3111 BiomedicineCHARACTERIZATION
researchProduct